Table of Content

1 Cancer Immunotherapies Market Overview
1.1 Cancer Immunotherapies Product Scope
1.2 Cancer Immunotherapies Segment by Type
1.2.1 Global Cancer Immunotherapies Sales by Type (2016 & 2021 & 2027)
1.2.2 Monoclonal Antibodies (MABs)
1.2.3 Cancer Vaccines
1.2.4 Immunomodulators
1.2.5 Adoptive Cell transfer
1.2.6 Checkpoint Inhibitors
1.3 Cancer Immunotherapies Segment by Application
1.3.1 Global Cancer Immunotherapies Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Breast Cancer
1.3.3 Leukemia
1.3.4 Lymphoma
1.3.5 Melanoma
1.3.6 Colorectal Cancer
1.3.7 Non-Small Cell Lung Cancer
1.4 Cancer Immunotherapies Market Estimates and Forecasts (2016-2027)
1.4.1 Global Cancer Immunotherapies Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Cancer Immunotherapies Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Cancer Immunotherapies Price Trends (2016-2027)

2 Cancer Immunotherapies Estimates and Forecasts by Region
2.1 Global Cancer Immunotherapies Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Cancer Immunotherapies Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Cancer Immunotherapies Sales Market Share by Region (2016-2021)
2.2.2 Global Cancer Immunotherapies Revenue Market Share by Region (2016-2021)
2.3 Global Cancer Immunotherapies Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Cancer Immunotherapies Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Cancer Immunotherapies Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Cancer Immunotherapies Estimates and Projections (2016-2027)
2.4.2 Europe Cancer Immunotherapies Estimates and Projections (2016-2027)
2.4.3 China Cancer Immunotherapies Estimates and Projections (2016-2027)
2.4.4 Japan Cancer Immunotherapies Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Cancer Immunotherapies Estimates and Projections (2016-2027)
2.4.6 India Cancer Immunotherapies Estimates and Projections (2016-2027)
3 Global Cancer Immunotherapies Competition Landscape by Players
3.1 Global Top Cancer Immunotherapies Players by Sales (2016-2021)
3.2 Global Top Cancer Immunotherapies Players by Revenue (2016-2021)
3.3 Global Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cancer Immunotherapies as of 2020)
3.4 Global Cancer Immunotherapies Average Price by Company (2016-2021)
3.5 Manufacturers Cancer Immunotherapies Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Cancer Immunotherapies Market Size by Type
4.1 Global Cancer Immunotherapies Historic Market Review by Type (2016-2021)
4.1.1 Global Cancer Immunotherapies Sales Market Share by Type (2016-2021)
4.1.2 Global Cancer Immunotherapies Revenue Market Share by Type (2016-2021)
4.1.3 Global Cancer Immunotherapies Price by Type (2016-2021)
4.2 Global Cancer Immunotherapies Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Cancer Immunotherapies Sales Forecast by Type (2022-2027)
4.2.2 Global Cancer Immunotherapies Revenue Forecast by Type (2022-2027)
4.2.3 Global Cancer Immunotherapies Price Forecast by Type (2022-2027)
5 Global Cancer Immunotherapies Market Size by Application
5.1 Global Cancer Immunotherapies Historic Market Review by Application (2016-2021)
5.1.1 Global Cancer Immunotherapies Sales Market Share by Application (2016-2021)
5.1.2 Global Cancer Immunotherapies Revenue Market Share by Application (2016-2021)
5.1.3 Global Cancer Immunotherapies Price by Application (2016-2021)
5.2 Global Cancer Immunotherapies Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Cancer Immunotherapies Sales Forecast by Application (2022-2027)
5.2.2 Global Cancer Immunotherapies Revenue Forecast by Application (2022-2027)
5.2.3 Global Cancer Immunotherapies Price Forecast by Application (2022-2027)

6 North America Cancer Immunotherapies Market Facts & Figures
6.1 North America Cancer Immunotherapies Sales by Company
6.1.1 North America Cancer Immunotherapies Sales by Company (2016-2021)
6.1.2 North America Cancer Immunotherapies Revenue by Company (2016-2021)
6.2 North America Cancer Immunotherapies Sales Breakdown by Type
6.2.1 North America Cancer Immunotherapies Sales Breakdown by Type (2016-2021)
6.2.2 North America Cancer Immunotherapies Sales Breakdown by Type (2022-2027)
6.3 North America Cancer Immunotherapies Sales Breakdown by Application
6.3.1 North America Cancer Immunotherapies Sales Breakdown by Application (2016-2021)
6.3.2 North America Cancer Immunotherapies Sales Breakdown by Application (2022-2027)

7 Europe Cancer Immunotherapies Market Facts & Figures
7.1 Europe Cancer Immunotherapies Sales by Company
7.1.1 Europe Cancer Immunotherapies Sales by Company (2016-2021)
7.1.2 Europe Cancer Immunotherapies Revenue by Company (2016-2021)
7.2 Europe Cancer Immunotherapies Sales Breakdown by Type
7.2.1 Europe Cancer Immunotherapies Sales Breakdown by Type (2016-2021)
7.2.2 Europe Cancer Immunotherapies Sales Breakdown by Type (2022-2027)
7.3 Europe Cancer Immunotherapies Sales Breakdown by Application
7.3.1 Europe 145 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 145 Sales Breakdown by Application (2022-2027)

8 China Cancer Immunotherapies Market Facts & Figures
8.1 China Cancer Immunotherapies Sales by Company
8.1.1 China Cancer Immunotherapies Sales by Company (2016-2021)
8.1.2 China Cancer Immunotherapies Revenue by Company (2016-2021)
8.2 China Cancer Immunotherapies Sales Breakdown by Type
8.2.1 China Cancer Immunotherapies Sales Breakdown by Type (2016-2021)
8.2.2 China Cancer Immunotherapies Sales Breakdown by Type (2022-2027)
8.3 China Cancer Immunotherapies Sales Breakdown by Application
8.3.1 China 316 Sales Breakdown by Application (2016-2021)
8.3.2 China 316 Sales Breakdown by Application (2022-2027)

9 Japan Cancer Immunotherapies Market Facts & Figures
9.1 Japan Cancer Immunotherapies Sales by Company
9.1.1 Japan Cancer Immunotherapies Sales by Company (2016-2021)
9.1.2 Japan Cancer Immunotherapies Revenue by Company (2016-2021)
9.2 Japan Cancer Immunotherapies Sales Breakdown by Type
9.2.1 Japan Cancer Immunotherapies Sales Breakdown by Type (2016-2021)
9.2.2 Japan Cancer Immunotherapies Sales Breakdown by Type (2022-2027)
9.3 Japan Cancer Immunotherapies Sales Breakdown by Application
9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Cancer Immunotherapies Market Facts & Figures
10.1 Southeast Asia Cancer Immunotherapies Sales by Company
10.1.1 Southeast Asia Cancer Immunotherapies Sales by Company (2016-2021)
10.1.2 Southeast Asia Cancer Immunotherapies Revenue by Company (2016-2021)
10.2 Southeast Asia Cancer Immunotherapies Sales Breakdown by Type
10.2.1 Southeast Asia Cancer Immunotherapies Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Cancer Immunotherapies Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Cancer Immunotherapies Sales Breakdown by Application
10.3.1 Southeast Asia K Units Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia K Units Sales Breakdown by Application (2022-2027)

11 India Cancer Immunotherapies Market Facts & Figures
11.1 India Cancer Immunotherapies Sales by Company
11.1.1 India Cancer Immunotherapies Sales by Company (2016-2021)
11.1.2 India Cancer Immunotherapies Revenue by Company (2016-2021)
11.2 India Cancer Immunotherapies Sales Breakdown by Type
11.2.1 India Cancer Immunotherapies Sales Breakdown by Type (2016-2021)
11.2.2 India Cancer Immunotherapies Sales Breakdown by Type (2022-2027)
11.3 India Cancer Immunotherapies Sales Breakdown by Application
11.3.1 India Cancer Immunotherapies Sales Breakdown by Application (2016-2021)
11.3.2 India Cancer Immunotherapies Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Cancer Immunotherapies Business
12.1 Amgen
12.1.1 Amgen Corporation Information
12.1.2 Amgen Business Overview
12.1.3 Amgen Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Amgen Cancer Immunotherapies Products Offered
12.1.5 Amgen Recent Development
12.2 AstraZeneca
12.2.1 AstraZeneca Corporation Information
12.2.2 AstraZeneca Business Overview
12.2.3 AstraZeneca Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
12.2.4 AstraZeneca Cancer Immunotherapies Products Offered
12.2.5 AstraZeneca Recent Development
12.3 Roche
12.3.1 Roche Corporation Information
12.3.2 Roche Business Overview
12.3.3 Roche Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Roche Cancer Immunotherapies Products Offered
12.3.5 Roche Recent Development
12.4 Bristol-Myers Squibb
12.4.1 Bristol-Myers Squibb Corporation Information
12.4.2 Bristol-Myers Squibb Business Overview
12.4.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Bristol-Myers Squibb Cancer Immunotherapies Products Offered
12.4.5 Bristol-Myers Squibb Recent Development
12.5 Bayer
12.5.1 Bayer Corporation Information
12.5.2 Bayer Business Overview
12.5.3 Bayer Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Bayer Cancer Immunotherapies Products Offered
12.5.5 Bayer Recent Development
12.6 Merck
12.6.1 Merck Corporation Information
12.6.2 Merck Business Overview
12.6.3 Merck Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Merck Cancer Immunotherapies Products Offered
12.6.5 Merck Recent Development
12.7 ARMO BioSciences (Eli Lilly)
12.7.1 ARMO BioSciences (Eli Lilly) Corporation Information
12.7.2 ARMO BioSciences (Eli Lilly) Business Overview
12.7.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
12.7.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Products Offered
12.7.5 ARMO BioSciences (Eli Lilly) Recent Development
12.8 Novartis
12.8.1 Novartis Corporation Information
12.8.2 Novartis Business Overview
12.8.3 Novartis Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Novartis Cancer Immunotherapies Products Offered
12.8.5 Novartis Recent Development
12.9 Pfizer
12.9.1 Pfizer Corporation Information
12.9.2 Pfizer Business Overview
12.9.3 Pfizer Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Pfizer Cancer Immunotherapies Products Offered
12.9.5 Pfizer Recent Development
12.10 Johnson & Johnson
12.10.1 Johnson & Johnson Corporation Information
12.10.2 Johnson & Johnson Business Overview
12.10.3 Johnson & Johnson Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Johnson & Johnson Cancer Immunotherapies Products Offered
12.10.5 Johnson & Johnson Recent Development
12.11 AbbVie
12.11.1 AbbVie Corporation Information
12.11.2 AbbVie Business Overview
12.11.3 AbbVie Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
12.11.4 AbbVie Cancer Immunotherapies Products Offered
12.11.5 AbbVie Recent Development
12.12 Gilead Sciences
12.12.1 Gilead Sciences Corporation Information
12.12.2 Gilead Sciences Business Overview
12.12.3 Gilead Sciences Cancer Immunotherapies Sales, Revenue and Gross Margin (2016-2021)
12.12.4 Gilead Sciences Cancer Immunotherapies Products Offered
12.12.5 Gilead Sciences Recent Development

13 Cancer Immunotherapies Manufacturing Cost Analysis
13.1 Cancer Immunotherapies Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Cancer Immunotherapies
13.4 Cancer Immunotherapies Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Cancer Immunotherapies Distributors List
14.3 Cancer Immunotherapies Customers

15 Market Dynamics
15.1 Cancer Immunotherapies Market Trends
15.2 Cancer Immunotherapies Drivers
15.3 Cancer Immunotherapies Market Challenges
15.4 Cancer Immunotherapies Market Restraints

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Cancer Immunotherapies Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027)
Table 2. Global Cancer Immunotherapies Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027)
Table 3. Global Cancer Immunotherapies Market Size (US$ Million) by Region: 2016 VS 2021 &2027
Table 4. Global Cancer Immunotherapies Sales (K Units) by Region (2016-2021)
Table 5. Global Cancer Immunotherapies Sales Market Share by Region (2016-2021)
Table 6. Global Cancer Immunotherapies Revenue (US$ Million) Market Share by Region (2016-2021))
Table 7. Global Cancer Immunotherapies Revenue Share by Region (2016-2021)
Table 8. Global Cancer Immunotherapies Sales (K Units) Forecast by Region (2022-2027)
Table 9. Global Cancer Immunotherapies Sales Market Share Forecast by Region (2022-2027)
Table 10. Global Cancer Immunotherapies Revenue (US$ Million) Forecast by Region (2022-2027)
Table 11. Global Cancer Immunotherapies Revenue Share Forecast by Region (2022-2027)
Table 12. Global Cancer Immunotherapies Sales (K Units) of Key Companies (2016-2021)
Table 13. Global Cancer Immunotherapies Sales Share by Company (2016-2021)
Table 14. Global Cancer Immunotherapies Revenue (US$ Million) by Company (2016-2021)
Table 15. Global Cancer Immunotherapies Revenue Share by Company (2016-2021)
Table 16. Global Cancer Immunotherapies by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Immunotherapies as of 2020)
Table 17. Global Cancer Immunotherapies Average Price (USD/Unit) of Key Company (2016-2021)
Table 18. Manufacturers Cancer Immunotherapies Manufacturing Sites and Area Served
Table 19. Manufacturers Cancer Immunotherapies Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Global Cancer Immunotherapies Sales (K Units) by Type (2016-2021)
Table 22. Global Cancer Immunotherapies Sales Share by Type (2016-2021)
Table 23. Global Cancer Immunotherapies Revenue (US$ Million) Market Share by Type (2016-2021)
Table 24. Global Cancer Immunotherapies Price (USD/Unit) by Type (2016-2021)
Table 25. Global Cancer Immunotherapies Sales Share by Type (2022-2027)
Table 26. Global Cancer Immunotherapies Revenue (US$ Million) Market Share by Type (2022-2027)
Table 27. Global Cancer Immunotherapies Revenue Share by Type (2022-2027)
Table 28. Global Cancer Immunotherapies Price (USD/Unit) by Type (2022-2027)
Table 29. Global Cancer Immunotherapies Sales (K Units) by Application (2016-2021)
Table 30. Global Cancer Immunotherapies Sales Share by Application (2016-2021)
Table 31. Global Cancer Immunotherapies Revenue (US$ Million) Market Share by Application (2016-2021)
Table 32. Global Cancer Immunotherapies Price (USD/Unit) by Application (2016-2021)
Table 33. Global Cancer Immunotherapies Sales (K Units) by Application (2022-2027)
Table 34. Global Cancer Immunotherapies Sales Share by Application (2022-2027)
Table 35. Global Cancer Immunotherapies Revenue (US$ Million) Market Share by Application (2022-2027)
Table 36. Global Cancer Immunotherapies Revenue Share by Application (2022-2027)
Table 37. Global Cancer Immunotherapies Price (USD/Unit) by Application (2022-2027)
Table 38. North America Cancer Immunotherapies Sales (K Units) by Company (2016-2021)
Table 39. North America Cancer Immunotherapies Sales Market Share by Company (2016-2021)
Table 40. North America Cancer Immunotherapies Revenue by Company (2016-2021) & (US$ Million)
Table 41. North America Cancer Immunotherapies Revenue Market Share by Company (2016-2021)
Table 42. North America Cancer Immunotherapies Sales by Type (2016-2021) & (K Units)
Table 43. North America Cancer Immunotherapies Sales Market Share by Type (2016-2021)
Table 44. North America Cancer Immunotherapies Sales by Type (2022-2027) & (K Units)
Table 45. North America Cancer Immunotherapies Sales Market Share by Type (2022-2027)
Table 46. North America Cancer Immunotherapies Sales by Application (2016-2021) & (K Units)
Table 47. North America Cancer Immunotherapies Sales Market Share by Application (2016-2021)
Table 48. North America Cancer Immunotherapies Sales by Application (2022-2027) & (K Units)
Table 49. North America Cancer Immunotherapies Sales Market Share by Application (2022-2027)
Table 50. Europe Cancer Immunotherapies Sales (K Units) by Company (2016-2021)
Table 51. Europe Cancer Immunotherapies Sales Market Share by Company (2016-2021)
Table 52. Europe Cancer Immunotherapies Revenue by Company (2016-2021) & (US$ Million)
Table 53. Europe Cancer Immunotherapies Revenue Market Share by Company (2016-2021)
Table 54. Europe Cancer Immunotherapies Sales by Type (2016-2021) & (K Units)
Table 55. Europe Cancer Immunotherapies Sales Market Share by Type (2016-2021)
Table 56. Europe Cancer Immunotherapies Sales by Type (2022-2027) & (K Units)
Table 57. Europe Cancer Immunotherapies Sales Market Share by Type (2022-2027)
Table 58. Europe Cancer Immunotherapies Sales by Application (2016-2021) & (K Units)
Table 59. Europe Cancer Immunotherapies Sales Market Share by Application (2016-2021)
Table 60. Europe Cancer Immunotherapies Sales by Application (2022-2027) & (K Units)
Table 61. Europe Cancer Immunotherapies Sales Market Share by Application (2022-2027)
Table 62. China Cancer Immunotherapies Sales (K Units) by Company (2016-2021)
Table 63. China Cancer Immunotherapies Sales Market Share by Company (2016-2021)
Table 64. China Cancer Immunotherapies Revenue by Company (2016-2021) & (US$ Million)
Table 65. China Cancer Immunotherapies Revenue Market Share by Company (2016-2021)
Table 66. China Cancer Immunotherapies Sales by Type (2016-2021) & (K Units)
Table 67. China Cancer Immunotherapies Sales Market Share by Type (2016-2021)
Table 68. China Cancer Immunotherapies Sales by Type (2022-2027) & (K Units)
Table 69. China Cancer Immunotherapies Sales Market Share by Type (2022-2027)
Table 70. China Cancer Immunotherapies Sales by Application (2016-2021) & (K Units)
Table 71. China Cancer Immunotherapies Sales Market Share by Application (2016-2021)
Table 72. China Cancer Immunotherapies Sales by Application (2022-2027) & (K Units)
Table 73. China Cancer Immunotherapies Sales Market Share by Application (2022-2027)
Table 74. Japan Cancer Immunotherapies Sales (K Units) by Company (2016-2021)
Table 75. Japan Cancer Immunotherapies Sales Market Share by Company (2016-2021)
Table 76. Japan Cancer Immunotherapies Revenue by Company (2016-2021) & (US$ Million)
Table 77. Japan Cancer Immunotherapies Revenue Market Share by Company (2016-2021)
Table 78. Japan Cancer Immunotherapies Sales by Type (2016-2021) & (K Units)
Table 79. Japan Cancer Immunotherapies Sales Market Share by Type (2016-2021)
Table 80. Japan Cancer Immunotherapies Sales by Type (2022-2027) & (K Units)
Table 81. Japan Cancer Immunotherapies Sales Market Share by Type (2022-2027)
Table 82. Japan Cancer Immunotherapies Sales by Application (2016-2021) & (K Units)
Table 83. Japan Cancer Immunotherapies Sales Market Share by Application (2016-2021)
Table 84. Japan Cancer Immunotherapies Sales by Application (2022-2027) & (K Units)
Table 85. Japan Cancer Immunotherapies Sales Market Share by Application (2022-2027)
Table 86. Southeast Asia Cancer Immunotherapies Sales (K Units) by Company (2016-2021)
Table 87. Southeast Asia Cancer Immunotherapies Sales Market Share by Company (2016-2021)
Table 88. Southeast Asia Cancer Immunotherapies Revenue by Company (2016-2021) & (US$ Million)
Table 89. Southeast Asia Cancer Immunotherapies Revenue Market Share by Company (2016-2021)
Table 90. Southeast Asia Cancer Immunotherapies Sales by Type (2016-2021) & (K Units)
Table 91. Southeast Asia Cancer Immunotherapies Sales Market Share by Type (2016-2021)
Table 92. Southeast Asia Cancer Immunotherapies Sales by Type (2022-2027) & (K Units)
Table 93. Southeast Asia Cancer Immunotherapies Sales Market Share by Type (2022-2027)
Table 94. Southeast Asia Cancer Immunotherapies Sales by Application (2016-2021) & (K Units)
Table 95. Southeast Asia Cancer Immunotherapies Sales Market Share by Application (2016-2021)
Table 96. Southeast Asia Cancer Immunotherapies Sales by Application (2022-2027) & (K Units)
Table 97. Southeast Asia Cancer Immunotherapies Sales Market Share by Application (2022-2027)
Table 98. India Cancer Immunotherapies Sales (K Units) by Company (2016-2021)
Table 99. India Cancer Immunotherapies Sales Market Share by Company (2016-2021)
Table 100. India Cancer Immunotherapies Revenue by Company (2016-2021) & (US$ Million)
Table 101. India Cancer Immunotherapies Revenue Market Share by Company (2016-2021)
Table 102. India Cancer Immunotherapies Sales by Type (2016-2021) & (K Units)
Table 103. India Cancer Immunotherapies Sales Market Share by Type (2016-2021)
Table 104. India Cancer Immunotherapies Sales by Type (2022-2027) & (K Units)
Table 105. India Cancer Immunotherapies Sales Market Share by Type (2022-2027)
Table 106. India Cancer Immunotherapies Sales by Application (2016-2021) & (K Units)
Table 107. India Cancer Immunotherapies Sales Market Share by Application (2016-2021)
Table 108. India Cancer Immunotherapies Sales by Application (2022-2027) & (K Units)
Table 109. India Cancer Immunotherapies Sales Market Share by Application (2022-2027)
Table 110. Amgen Corporation Information
Table 111. Amgen Description and Business Overview
Table 112. Amgen Cancer Immunotherapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 113. Amgen Cancer Immunotherapies Product
Table 114. Amgen Recent Development
Table 115. AstraZeneca Corporation Information
Table 116. AstraZeneca Description and Business Overview
Table 117. AstraZeneca Cancer Immunotherapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 118. AstraZeneca Cancer Immunotherapies Product
Table 119. AstraZeneca Recent Development
Table 120. Roche Corporation Information
Table 121. Roche Description and Business Overview
Table 122. Roche Cancer Immunotherapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 123. Roche Cancer Immunotherapies Product
Table 124. Roche Recent Development
Table 125. Bristol-Myers Squibb Corporation Information
Table 126. Bristol-Myers Squibb Description and Business Overview
Table 127. Bristol-Myers Squibb Cancer Immunotherapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 128. Bristol-Myers Squibb Cancer Immunotherapies Product
Table 129. Bristol-Myers Squibb Recent Development
Table 130. Bayer Corporation Information
Table 131. Bayer Description and Business Overview
Table 132. Bayer Cancer Immunotherapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 133. Bayer Cancer Immunotherapies Product
Table 134. Bayer Recent Development
Table 135. Merck Corporation Information
Table 136. Merck Description and Business Overview
Table 137. Merck Cancer Immunotherapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 138. Merck Cancer Immunotherapies Product
Table 139. Merck Recent Development
Table 140. ARMO BioSciences (Eli Lilly) Corporation Information
Table 141. ARMO BioSciences (Eli Lilly) Description and Business Overview
Table 142. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 143. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product
Table 144. ARMO BioSciences (Eli Lilly) Recent Development
Table 145. Novartis Corporation Information
Table 146. Novartis Cancer Immunotherapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 147. Novartis Description and Business Overview
Table 148. Novartis Cancer Immunotherapies Product
Table 149. Novartis Recent Development
Table 150. Pfizer Corporation Information
Table 151. Pfizer Cancer Immunotherapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 152. Pfizer Description and Business Overview
Table 153. Pfizer Cancer Immunotherapies Product
Table 154. Pfizer Recent Development
Table 155. Johnson & Johnson Corporation Information
Table 156. Johnson & Johnson Description and Business Overview
Table 157. Johnson & Johnson Cancer Immunotherapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 158. Johnson & Johnson Cancer Immunotherapies Product
Table 159. Johnson & Johnson Recent Development
Table 160. AbbVie Corporation Information
Table 161. AbbVie Description and Business Overview
Table 162. AbbVie Cancer Immunotherapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 163. AbbVie Cancer Immunotherapies Product
Table 164. AbbVie Recent Development
Table 165. Gilead Sciences Corporation Information
Table 166. Gilead Sciences Description and Business Overview
Table 167. Gilead Sciences Cancer Immunotherapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 168. Gilead Sciences Cancer Immunotherapies Product
Table 169. Gilead Sciences Recent Development
Table 170. Production Base and Market Concentration Rate of Raw Material
Table 171. Key Suppliers of Raw Materials
Table 172. Cancer Immunotherapies Distributors List
Table 173. Cancer Immunotherapies Customers List
Table 174. Cancer Immunotherapies Market Trends
Table 175. Cancer Immunotherapies Market Drivers
Table 176. Cancer Immunotherapies Market Challenges
Table 177. Cancer Immunotherapies Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Cancer Immunotherapies Product Picture
Figure 2. Global Cancer Immunotherapies Sales Market Share by Type in 2021 & 2027
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Cancer Immunotherapies Sales Market Share by Application in 2021 & 2027
Figure 6. Breast Cancer Examples
Figure 7. Leukemia Examples
Figure 8. Lymphoma Examples
Figure 9. Melanoma Examples
Figure 10. Colorectal Cancer Examples
Figure 11. Non-Small Cell Lung Cancer Examples
Figure 12. Global Cancer Immunotherapies Sales, (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Cancer Immunotherapies Sales Growth Rate (2016-2027) & (US$ Million)
Figure 14. Global Cancer Immunotherapies Sales (K Units) Growth Rate (2016-2027)
Figure 15. Global Cancer Immunotherapies Price Trends Growth Rate (2016-2027) (USD/Unit)
Figure 16. Global Cancer Immunotherapies Revenue Market Share by Region: 2016 VS 2021
Figure 17. Global Cancer Immunotherapies Revenue Market Share by Region: 2021 VS 2027
Figure 18. North America Cancer Immunotherapies Revenue (Million USD) Growth Rate (2016-2027)
Figure 19. North America Cancer Immunotherapies Sales (K Units) Growth Rate (2016-2027)
Figure 20. Europe Cancer Immunotherapies Revenue (Million USD) Growth Rate (2016-2027)
Figure 21. Europe Cancer Immunotherapies Sales (Million USD) Growth Rate (2016-2027)
Figure 22. China Cancer Immunotherapies Revenue (Million USD) Growth Rate (2016-2027)
Figure 23. China Cancer Immunotherapies Sales (Million USD) and Growth Rate (2016-2027)
Figure 24. Japan Cancer Immunotherapies Revenue (Million USD) Growth Rate (2016-2027)
Figure 25. Japan Cancer Immunotherapies Sales (Million USD) Growth Rate (2016-2027)
Figure 26. Southeast Asia Cancer Immunotherapies Revenue (Million USD) Growth Rate (2016-2027)
Figure 27. Southeast Asia Cancer Immunotherapies Sales (Million USD) Growth Rate (2016-2027)
Figure 28. India Cancer Immunotherapies Revenue (Million USD) Growth Rate (2016-2027)
Figure 29. India Cancer Immunotherapies Sales (Million USD) Growth Rate (2016-2027)
Figure 30. Global 5 Largest Cancer Immunotherapies Players Market Share by Revenue in Cancer Immunotherapies: 2016 & 2020
Figure 31. Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 32. Global Cancer Immunotherapies Revenue Share by Type (2016-2021)
Figure 33. Global Cancer Immunotherapies Revenue Growth Rate by Type in 2016 & 2020
Figure 34. Global Cancer Immunotherapies Revenue Share by Application (2016-2021)
Figure 35. Global Cancer Immunotherapies Revenue Growth Rate by Application in 2016 & 2020
Figure 36. North America Cancer Immunotherapies Sales Market Share by Type in 2020
Figure 37. North America Cancer Immunotherapies Sales Market Share by Application in 2020
Figure 38. Europe Cancer Immunotherapies Sales Market Share by Type in 2020
Figure 39. Europe Cancer Immunotherapies Sales Market Share by Application in 2020
Figure 40. China Cancer Immunotherapies Sales Market Share by Type in 2020
Figure 41. China Cancer Immunotherapies Sales Market Share by Application in 2020
Figure 42. Japan Cancer Immunotherapies Sales Market Share by Type in 2020
Figure 43. Japan Cancer Immunotherapies Sales Market Share by Application in 2020
Figure 44. Southeast Asia Cancer Immunotherapies Sales Market Share by Type in 2020
Figure 45. Southeast Asia Cancer Immunotherapies Sales Market Share by Application in 2020
Figure 46. India Cancer Immunotherapies Sales Market Share by Type in 2020
Figure 47. India Cancer Immunotherapies Sales Market Share by Application in 2020
Figure 48. Key Raw Materials Price Trend
Figure 49. Manufacturing Cost Structure of Cancer Immunotherapies
Figure 50. Manufacturing Process Analysis of Cancer Immunotherapies
Figure 51. Cancer Immunotherapies Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed